IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
1.010
-0.005 (-0.49%)
At close: Jun 27, 2025, 4:00 PM
1.000
-0.010 (-0.99%)
After-hours: Jun 27, 2025, 7:59 PM EDT

Company Description

IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally.

The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.

It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors.

The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

IceCure Medical Ltd
IceCure Medical logo
Country Israel
Founded 2006
Industry Medical Devices
Sector Healthcare
Employees 66
CEO Eyal Shamir

Contact Details

Address:
7 Ha’Eshel Street, PO Box 3163
Caesarea, 3079504
Israel
Phone 972 4 623 0333
Website icecure-medical.com

Stock Details

Ticker Symbol ICCM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $0.00
CIK Code 0001584371
CUSIP Number M53071136
ISIN Number IL0011224156
SIC Code 3841

Key Executives

Name Position
Eyal Shamir Chief Executive Officer and Director
Ronen Tsimerman CPA Chief Financial Officer and Chief Operating Officer
Tlalit Bussi Tel-Tzure Vice President of Business Development and Global Marketing
Shad Good Vice President of Sales for North America
Merav Nir Dotan Vice President of Human Resources
Galit Malik Vice President of Operations and Service

Latest SEC Filings

Date Type Title
Jun 25, 2025 FWP Free Writing Prospectus
Jun 25, 2025 6-K Report of foreign issuer
Jun 25, 2025 F-1/A [Amend] Registration statement for certain foreign private issuers
Jun 16, 2025 F-1 Registration statement for certain foreign private issuers
Jun 16, 2025 RW Filing
Jun 9, 2025 6-K Report of foreign issuer
May 28, 2025 6-K Report of foreign issuer
May 23, 2025 DRS [Cover] Draft Registration Statement
May 21, 2025 6-K Report of foreign issuer
May 15, 2025 6-K Report of foreign issuer